$NVCR News

Wells Fargo Maintains Equal-Weight on NovoCure, Raises Price Target to $17

NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet

Evercore ISI Group Maintains Outperform on NovoCure, Raises Price Target to $20

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump

NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript

NovoCure Limited 2026 Q1 - Results - Earnings Call Presentation

NovoCure Raises FY2026 Sales Guidance from $675.000M-$705.000M to $690.000M-$710.000M vs $692.115M Est

NovoCure Q1 EPS $(0.62) Misses $(0.51) Estimate, Sales $174.055M Beat $167.867M Estimate

Wedbush Reiterates Neutral on NovoCure, Maintains $18 Price Target

NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed?

Novocure to Report First Quarter 2026 Financial Results

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump

Novocure Announces Results From Phase 2 PANOVA-4 Trial Of TTFields Therapy Concomitant With Atezolizumab, Gem/Nab-Pac As First-Line Treatment For mPDAC

NovoCure Limited 2025 Q4 - Results - Earnings Call Presentation

NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Novocure Secures Japan National Health Insurance Reimbursement For Optune Lua In Advanced Non-Small Cell Lung Cancer, Enabling National Launch